西妥昔单抗联合阿维鲁单抗与放疗治疗晚期头颈鳞癌的I期试验
这项I期可行性试验纳入10例不适合顺铂治疗的晚期头颈鳞癌患者,接受西妥昔单抗放疗联用阿维鲁单抗。未出现4-5级毒性,3级免疫相关毒性可管理,8例可评估患者中4例复发。结论认为该方案可行,支持开展更大规模疗效试验。
要点
- 不适合顺铂的晚期头颈鳞癌患者中,西妥昔单抗放疗联用阿维鲁单抗可行。
- 未出现4-5级毒性,3级免疫相关毒性短暂且可管理。
- 8例可评估患者中4例(50%)在中位12个月随访内复发。
核心结论
- 西妥昔单抗放疗联用阿维鲁单抗在不适合顺铂治疗的晚期头颈鳞癌患者中可行。
- 免疫相关毒性短暂且可管理,放疗相关毒性与标准治疗一致。
研究设计与样本
- I期可行性试验,计划入组10例,注册号NCT02938273。
- 人群为不适合顺铂治疗的晚期头颈鳞癌患者。
- 方案为常规西妥昔单抗放疗联用阿维鲁单抗10 mg/kg每2周同期及4个月维持。
主要发现
- 10例入组患者中1例出现2级西妥昔单抗相关输注反应并在阿维鲁单抗给药前退出。
- 1例因个人原因在2程阿维鲁单抗和12次2Gy放疗后终止治疗。
- 8例可评估患者中2例分别因毒性和肿瘤进展在4程和8程阿维鲁单抗后停药。
- 未出现4-5级毒性;4例发生3级免疫相关毒性,其中1例3级斑丘疹予局部类固醇、1例3级肝酶升高和2例3级肺炎予大剂量泼尼松。
- 7例发生3级放疗相关毒性,无严重特定西妥昔单抗相关毒性;中位随访12(8-26)个月,8例中4例(50%)复发。
临床怎么用
- 该方案可作为不适合顺铂治疗的晚期头颈鳞癌患者的可行选择,但需监测免疫相关毒性。
- 3级免疫相关毒性(皮疹、肝酶升高、肺炎)经局部或大剂量泼尼松处理可管理。
局限性
- 为I期可行性试验,样本量小(计划10例),疗效证据有限。
- 仅8例可评估,随访时间短,需更大规模疗效试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiotherapy (RT) with cetuximab is an alternative for advanced-stage head and neck squamous cell carcinoma (HNSCC) patients who are unfit for cisplatin treatment. As 5-year overall survival is below 50%, it is of interest to test PD-L1 immune checkpoint blockade (avelumab) with cetuximab-RT in the curative setting. MATERIALS AND METHODS: Phase-I feasibility trial (planned n = 10, NCT02938273) of conventional cetuximab-RT with avelumab (concurrent 10 mg/kg Q2W + 4 months maintenance) for advanced-stage HNSCC patients unfit for cisplatin treatment. RESULTS: One of ten included patients experienced grade 2 cetuximab-related infusion reaction and withdrew from the study before avelumab was administered. One patient discontinued treatment after 2 courses of avelumab and 12×2Gy RT for personal reasons. In 2/8 remaining patients, avelumab was stopped after 4 and 8 courses because of toxicity and tumor progression, respectively. There was no grade 4-5 toxicity. Grade 3 immune-related toxicity was manageable and occurred in 4 patients. One patient was treated with topical steroids for grade 3 maculopapular rash and 3 patients received high-dose prednisone for grade 3 elevated liver enzymes (n = 1) and pneumonitis (n = 2). Seven patients experienced grade 3 RT-related toxicity with no severe specific cetuximab-related toxicity. Tumor recurrence occurred in 4/8 patients (50%) after a median of 12 (8-26) months follow-up. CONCLUSION: Cetuximab-RT plus avelumab is feasible in patients with advanced-stage HNSCC who are unfit for cisplatin treatment. Immune-related toxicity was transient and manageable and radiotherapy-related toxicity was in accordance with standard of care. This pilot study provides grounds for larger efficacy trials.
引用
- Elbers JBW, Al-Mamgani A, Tesseslaar MET, et al. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. Radiother Oncol. 2019. PMID: 31563412. doi:10.1016/j.radonc.2019.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。